| 17.3001 1.5 (9.29%) | 09-19 14:39 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 24.09 |
1-year : | 28.14 |
| Resists | First : | 20.62 |
Second : | 24.09 |
| Pivot price | 16.35 |
|||
| Supports | First : | 16.53 |
Second : | 14 |
| MAs | MA(5) : | 16.72 |
MA(20) : | 16.42 |
| MA(100) : | 17.89 |
MA(250) : | 14.59 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 39.9 |
D(3) : | 36.7 |
| RSI | RSI(14): 57 |
|||
| 52-week | High : | 26.37 | Low : | 4.28 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CRVO ] has closed below upper band by 12.4%. Bollinger Bands are 21% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 17.03 - 17.13 | 17.13 - 17.21 |
| Low: | 15.45 - 15.58 | 15.58 - 15.67 |
| Close: | 15.63 - 15.82 | 15.82 - 15.96 |
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.
Wed, 18 Sep 2024
CervoMed (NASDAQ:CRVO) Now Covered by Analysts at Chardan Capital - MarketBeat
Thu, 12 Sep 2024
CervoMed (NASDAQ:CRVO) Shares Up 1.2% - MarketBeat
Sat, 31 Aug 2024
CervoMed Inc. (NASDAQ:CRVO) Short Interest Up 46.2% in August - MarketBeat
Tue, 27 Aug 2024
CervoMed to Participate in Upcoming Investor Conferences - StockTitan
Sat, 24 Aug 2024
We're Not Very Worried About CervoMed's (NASDAQ:CRVO) Cash Burn Rate - Simply Wall St
Mon, 12 Aug 2024
CervoMed Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - StockTitan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 8 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 35.2 (%) |
| Held by Institutions | 42 (%) |
| Shares Short | 1,070 (K) |
| Shares Short P.Month | 691 (K) |
| EPS | 2.3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.05 |
| Profit Margin | -52.3 % |
| Operating Margin | -91.1 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 91.1 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.16 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 7.79 |
| PEG Ratio | 0 |
| Price to Book value | 2.97 |
| Price to Sales | 15.38 |
| Price to Cash Flow | -19.47 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|